Penn Capital Management
AMRX icon

Penn Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Penn Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,181,176
Closed -$20.5M – 176
2026
Q2 		$20.5M Sell
1,181,176
-14,897
-1% -$204K 1.3% 27
2026
Q1 		$14.9M Buy
1,196,073
+194,122
+19% +$2.61M 1.15% 45
2025
Q4 		$12.7M Buy
+1,001,951
New +$11.5M 1.01% 56

Other funds holding AMRX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Tucker Asset Management
Tucker Asset Management Littleton, Colorado $406M AUM 20.49% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Penn Capital Management's AMRX Position: Q3 2026 in Review

Penn Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2026, closing a stake of 1,181,176 shares — an estimated $20.5M sold.

Penn Capital Management first reported a position in AMRX in Q4 2025 and held it in 3 quarters. The position peaked at $20.5M in Q2 2026. 148 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Penn Capital Management reported no remaining Amneal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Penn Capital Management sold 1,181,176 Amneal Pharmaceuticals shares in Q3 2026, an estimated $20.5M.
  • Penn Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Penn Capital Management's Amneal Pharmaceuticals position peaked at $20.5M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Penn Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.